Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation

被引:4
|
作者
Tufan, Abdurrahman [1 ]
Cerinic, Marco Matucci [2 ,3 ]
机构
[1] Gazi Univ, Div Rheumatol, Dept Internal Med, Ankara, Turkey
[2] Univ Florence, Div Rheumatol AOUC, Dept Expt & Clin Med, Florence, Italy
[3] IRCCS San Raffaele Hosp, Unit Immunol Rheumatol Allergy & Rare Dis UnIRAR, Milan, Italy
关键词
SARS-CoV-2; COVID-19; inflammation; cytokine storm; treatment; rheumatology; REGULATORY T-CELLS; CORONAVIRUS; CORTICOSTEROIDS; INTERLEUKIN-6; BARICITINIB; INHIBITION; PNEUMONIA; ANAKINRA; PLACEBO; PROTEIN;
D O I
10.3906/sag-2110-179
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the Wuhan province of China, almost two years ago, in December 2019, the novel Coronavirus 2019 has caused a severe involvement of the lower respiratory tract leading to an acute life-threatening respiratory syndrome, coronavirus disease-19 (COVID-19). Subsequently, coronavirus 2 (SARS-CoV-2) rapidly spread to the entire world causing a pandemic and affected every single person on earth either directly or indirectly with destroying all facets of social life and economy. Since the announcement of COVID-19 as a global pandemic, we have witnessed tremendous scientific work on all aspects of COVID-19 across the globe, which has never been witnessed before. The most remarkable achievement would be the introduction of vaccines, which provide protection from the severe infection and is the only premise for the control of disease. However, despite the tremendous work, the number of treatments either antiviral or immunomodulatory for infected patients are considerably limited, yet disease is causing substantial morbidity and mortality. COVID-19 follows heterogenous disease course among infected individuals, and dysregulated immune system is primarily responsible for the worse outcomes. Immune deficiency, being on corticosteroids for inflammatory diseases, delayed interferon response and advanced age adversely influence prognosis with impairing viral clearance. On the other hand, exuberant immune response with features of cytokine storm is the leading cause of death, which can be alleviated by use of either general immunosuppression with corticosteroids or selective neutralization of potent pro-inflammatory cytokines such as interleukin (IL)-1 and IL-6. Herein, we summarized the potential effective immunomodulatory treatments emphasizing in which patient population it is the most suitable, which dose should be administered, and which is the most appropriate timepoint to administer the drug during the course of the disease.
引用
收藏
页码:3391 / 3404
页数:14
相关论文
共 50 条
  • [1] COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs
    Tufan, Abdurrahman
    Avanoglu Guler, Aslihan
    Matucci-Cerinic, Marco
    [J]. TURKISH JOURNAL OF MEDICAL SCIENCES, 2020, 50 : 620 - 632
  • [2] Old and new antirheumatic drugs for the treatment of COVID-19
    Benucci, Maurizio
    Damiani, Arianna
    Infantino, Maria
    Manfredi, Mariangela
    Quartuccio, Luca
    [J]. JOINT BONE SPINE, 2020, 87 (03) : 195 - 197
  • [3] Hyperinflammation and Immune Response Generation in COVID-19
    Mishra, Kamla Prasad
    Singh, Ajay Kumar
    Singh, Shashi Bala
    [J]. NEUROIMMUNOMODULATION, 2021, 27 (02) : 80 - 86
  • [4] MITOCHONDRIAL DYSFUNCTION AND HYPERINFLAMMATION IN PEDIATRIC COVID-19 INFECTION
    Kim, Daniel
    Rakes, Lauren
    Mcguire, John
    [J]. CRITICAL CARE MEDICINE, 2024, 52
  • [5] Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept
    Valentini, Marco
    Zmerly, Hassan
    [J]. JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY, 2020, 27 (02): : E14 - E25
  • [6] Immunopathology of Hyperinflammation in COVID-19
    Gustine, Joshua N.
    Jones, Dennis
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2021, 191 (01): : 4 - 17
  • [7] Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists
    Kawazoe, Mai
    Kihara, Mari
    Nanki, Toshihiro
    [J]. PHARMACEUTICALS, 2021, 14 (12)
  • [8] Severe COVID-19: Immunosuppression or Hyperinflammation?
    Liu, Ye
    Li, Yiming
    Xu, Dongxue
    Zhang, Jing
    Peng, Zhiyong
    [J]. SHOCK, 2021, 56 (02): : 188 - 199
  • [9] Management of hyperinflammation in COVID-19 patients
    Suberviola, Borja
    Cuenca Fito, Elena
    [J]. REVISTA ESPANOLA DE QUIMIOTERAPIA, 2022, 35 : 6 - 9
  • [10] Immune treatment in COVID-19
    Menendez, Rosario
    Gonzalez, Paula
    Latorre, Ana
    Mendez, Raul
    [J]. REVISTA ESPANOLA DE QUIMIOTERAPIA, 2022, 35 : 59 - 63